Related Experiment Videos
Fenfluramine: amphetamine congener that fails to maintain drug-taking behavior in the rhesus monkey
Abstract:
Fenfluramine, over a dose range from 0.003 to 3 milligrams per kilogram of body weight, failed to maintain self-injection behavior in rhesus monkeys that had initiated and maintained responding for cocaine or methohexital. This absence of a positive reinforcing effect could not be attributed to a slow onset of drug effect or to the use of behaviorally inactive doses. Fenfluramine, because of its distinctive properties, may produce fewer problems of human abuse than do amphetamine-type agents.
Insights
Fenfluramine did not support self-injection of cocaine or methohexital in rhesus monkeys, suggesting it may have a lower abuse potential compared to amphetamine-type drugs.
Area of Science:
- Pharmacology
- Neuroscience
- Behavioral Science
Background:
- Drug abuse and addiction remain significant public health challenges.
- Understanding the reinforcing properties of psychoactive substances is crucial for developing effective treatments.
- Fenfluramine's pharmacological profile differs from traditional stimulants, warranting investigation into its abuse potential.
Purpose of the Study:
- To evaluate the reinforcing effects of fenfluramine in a non-human primate model.
- To compare the abuse liability of fenfluramine with that of cocaine and methohexital.
Main Methods:
- Rhesus monkeys were trained to self-administer cocaine or methohexital.
- Fenfluramine was administered across a dose range (0.003–3 mg/kg) to assess its effect on self-injection behavior.
- Response rates and patterns were analyzed to determine reinforcing efficacy.
Main Results:
- Fenfluramine failed to maintain self-injection behavior for either cocaine or methohexital.
- The lack of effect was not due to delayed onset or inactive doses.
- No positive reinforcing effect of fenfluramine was observed.
Conclusions:
- Fenfluramine does not appear to possess positive reinforcing properties in this model.
- Its distinct pharmacological characteristics suggest a potentially lower risk of human abuse compared to amphetamine-type agents.
- Further research into fenfluramine's neurobiological mechanisms may inform the development of safer therapeutic agents.